NORFOLK AND WAVENEY STP THERAPEUTICS ADVISORY GROUP (TAG) SHARED CARE AGREEMENTNorfolk And • November 5th, 2024
Contract Type FiledNovember 5th, 2024Generic and Proprietary/Brand Name See Netformulary for up-to-date list of products. Methylphenidate plain: Generic, Ritalin®, Medikinet®Methylphenidate modified-release:Concerta XL®, Delmosart®, Matoride XL®, Xaggitin XL®, Xenidate XL®See appendix 1 for comparative costs of these once-daily methylphenidate products Equasym XL®, Medikinet XL®Dexamfetamine: GenericLisdexamfetamine: Elvanse®, Elvanse Adult®Atomoxetine: Strattera® Indications for shared care In line with NICE NG 87 (March 2018) stimulants and atomoxetine are indicated for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) as part of a treatment package where remedial measures alone prove insufficient.For newly diagnosed cases in adulthood:Specialist Initiation, with the GP taking over prescribing responsibility in line with this Shared Care Agreement1. Drug treatment is the first-line treatment for adults with ADHD with either moderate or severe levels of impairment.2. Methylphenidate or lisdexamfetamine sho